Yang D, de Graaf C, Yang L, et al. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R). J Biol Chem. 2016;291(25):12991-13004.
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H., & Barkas, F. (2026). GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence. Journal of central nervous system disease, 18, 11795735261444425.
Drucker D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism, 57, 101351. https://doi.org/10.1016/j.molmet.2021.101351
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular metabolism, 46, 101102.
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021). Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 41(1), 14–30.